Genmab — Juni 2023
-
Kort video: Gevinsthjemtagning i Novo, Zealand Pharma og Genmab : https://www.proinvestor.com/boards/113030
-
Grant of Restricted Stock Units and Warrants to Employees in Genmab https://www.proinvestor.com/investornyt/998687/grant-of-restricted-stock-units-and-warrants-to-employees-in-genmab
-
Aktier: 4 grunde til at investorerne har taget tyren ved hornene. Danske aktier i overhalingsbanen med fed energi fra Novo Nordisk https://www.proinvestor.com/boards/113062
-
Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas at European Hematology Association (EHA) Annual Meeting 2023 https://ir.genmab.com/news-releases/news-release-details/genmab-showcases-data-comprehensive-epcoritamab-development
-
Both Talquetamab and Epcoritamab on the COMP agenda for next week under '4. Review of orphan designation for orphan medicinal products
at time of initial marketing authorisation' https://www.ema.europa.eu/en/documents/agenda/agenda-comp-meeting-13-15-june-2023_en.pdf -
results from 2 cohorts in EPCORE NH2 investigating epcoritamab+rituximab & lenalidomide in patients with R/R FL. This combination showed potent anti-tumor activity and a manageable safety profile in patients with high-risk disease #lymsm https://twitter.com/lymphomahub/status/1667162491560837120
-
@NBahlis
presents results of the TRIMM-2 trial (talquetamab + daratumumab), targeting GPRC5D & CD38, ORR of 84% w/ response rate within 1st round of therapy.
**Impressively, 78.6% pts were refractory & heavily pre-exposed to a CD38 https://twitter.com/MyelomaCanada/status/1667475172201201664 https://twitter.com/MM_Hub/status/1667475083022024707 -
Follicular #lymphoma (#FL) accounts for ~20% of all non-Hodgkin’s lymphoma (NHL) cases globally and is the most common subtype of indolent, or slow growing, NHL. https://twitter.com/Genmab/status/1667275399364001793
-
Carvykti: https://haematologisktidsskrift.dk/sygdomme/myeloma/1190-finale-cartitude-1-data-storste-pfs-gevinst-for-tungt-forbehandlede-rrmm-patienter-til-dato.html. https://haematologisktidsskrift.dk/sygdomme/myeloma/1194-forste-data-fra-cartitude-4-meget-flotte-responser-hos-lenalidomid-refraktaere-myelomatose-patienter.html
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind